Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Withdrawn 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1Other hematologic neoplasm 1Lymphoid 1Breast 1

Conditions

Breast Neoplasms 3Sarcoma 1Lymphoma 1Hematologic Neoplasms 1

Interventions

pembrolizumab 10Gemcitabine 8Cyclophosphamide 7Filgrastim 5Docetaxel 5Carboplatin 5Trastuzumab 4Surveys and Questionnaires 4Nivolumab 4Doxorubicin 4Cisplatin 4poly ICLC 3pazopanib 3atezolizumab 3aldesleukin 3Taxes 3Radiotherapy 3Paclitaxel 3Oncolytic Virotherapy 3Irinotecan 3Ipilimumab 3Injections 3Drug Therapy 3Cetuximab 3Capecitabine 3Albumin-Bound Paclitaxel 3130-nm albumin-bound paclitaxel 3spartalizumab 2palbociclib 2liposomal doxorubicin 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Sarcoma × Pravastatin × Breast × Clear all
NCT04190433 2023-05-24

Autophagy Activation for the Alleviation of Cardiomyopathy Symptoms After Anthracycline Treatment, ATACAR Trial

Mayo Clinic

Phase 2 Withdrawn
BreastLymphoidOther hematologic neoplasmSarcoma

Breast Neoplasms, Lymphoma, Sarcoma, Hematologic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡